Association of NFE2L2 and KEAP1 haplotypes with amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 15, Issue 1-2, 2014, Pages 130-137

  Bergström, Petra ^a   Von Otter, Malin ^b   Nilsson, Staffan ^c   Nilsson, Ann Charloth ^d   Nilsson, Michael ^b,e   Andersen, Peter M ^d   Hammarsten, Ola ^a   Zetterberg, Henrik ^b,f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ALS; Amyotrophic lateral sclerosis; Haplotype; KEAP1; NFE2L2; Nrf2; Risk factor; SNP

Indexed keywords

KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2;

ADULT; AGED; ALLELE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPORADIC AMYOTROPHIC LATERAL SCLEROSIS; SWEDEN;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; BULBAR PALSY, PROGRESSIVE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MUSCULAR ATROPHY, SPINAL; NF-E2-RELATED FACTOR 2; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SWEDEN;

EID: 84895527015     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2013.839708     Document Type: Article

References (36)

1. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603-15.
2. Copple IM, Goldring CE, Kitteringham NR, Park BK. The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology. (Review). 2008;246: 24-33.
3. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes & Development. 1999; 13:76-86. (Pubitemid 29045117)
4. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Molecular and Cellular Biology. 2004; 24:8477-86. (Pubitemid 39245070)
5. Furukawa M, XiongY. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Molecular and Cellular Biology. 2005;25: 162-71. (Pubitemid 40039808)
6. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, Uchida K, et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Molecular and Cellular Biology. 2006;26:221-9.
7. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochemical and Biophysical Research Communications. 1997;236:313-22. (Pubitemid 27373291)
8. Alam J , Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. The Journal of Biological Chemistry. 1999;274:26071-8.
9. Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H: quinone oxidoreductase1 gene. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93:14960-5. (Pubitemid 26419078)
10. Schipper HM. Heme oxygenase expression in human central nervous system disorders. Free Radical Biology &Medicine. 2004;37:1995-2011. (Pubitemid 39491319)
11. van Muiswinkel FL, de Vos RA, Bol JG, Andringa G, Jansen Steur EN, Ross D, et al. Expression of NAD(P) H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiology of Aging. 2004;25: 1253-62. (Pubitemid 39094028)
12. Franklin CC, Backos DS, Mohar I, White CC, Forman HJ, Kavanagh TJ. Structure, function, and post-translational regulation of the catalytic and modifier subunits of glutamate cysteine ligase. Mol Aspects Med. 2009;30: 86-98.
13. Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the Cu/Zn superoxide dismutase gene. Current Neurology and Neuroscience Reports. 2006;6: 37-46. (Pubitemid 43154251)
14. Vargas MR, Pehar M, Cassina P, Martinez-Palma L, Thompson JA, Beckman JS, et al. Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. The Journal of Biological Chemistry. 2005;280:25571-9. (Pubitemid 40962264)
15. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615-22. (Pubitemid 46652435)
16. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes protects against neuro-degeneration in mouse models of familial amyotrophic lateral sclerosis . J Neurosci. 2008;28:13574-81.
17. Pehar M, Vargas MR, Robinson KM, Cassina P, Diaz-Amarilla PJ, HagenTM, et al. Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. J Neurosci. 2007;27:7777-85. (Pubitemid 47093805)
18. Sarlette A, Krampfl K, Grothe C, Neuhoff N, Dengler R, Petri S. Nuclear erythroid 2-related factor 2-antioxidative response element signalling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology. 2008;67: 1055-62.
19. Marczak ED, Marzec J, Zeldin DC, Kleeberger SR, Brown NJ, Pretorius M, et al. Polymorphisms in the transcription factor NRF2 and forearm vasodilator responses in humans. Pharmacogenet Genomics. 2012;22:620-8.
20. Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. Faseb J. 2007;21:2237-46. (Pubitemid 47026458)
21. Hua CC, Chang LC, Tseng JC, Chu CM, Liu YC, Shieh WB. Functional haplotypes in the promoter region of transcription factor Nrf2 in chronic obstructive pulmonary disease. Dis Markers. 2010;28:185-93.
22. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. Nrf2 gene promoter polymorphism is associated with ulcerative colitis in a Japanese population. Hepatogastroenterology. 2008;55:394-7. (Pubitemid 351741468)
23. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. The relationship between Helicobacter pylori infection and promoter polymorphism of the Nrf2 gene in chronic gastritis. International Journal of Molecular Medicine. 2007;19:143-8.
24. Guan CP, Zhou MN, Xu AE, Kang KF, Liu JF, Wei XD, et al. The susceptibility to vitiligo is associated with NF-E2-related factor2 (Nrf2) gene polymorphisms: a study on Chinese Han population . Exp Dermatol. 2008;17:1059-62.
25. McMahon M, Lamont DJ, Beattie KA, Hayes JD. Keap1 perceives stress via three sensors for the endogenous signalling molecules nitric oxide, zinc, and alkenals. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:18838-43.
26. Siedlinski M, Postma DS, Boer JM, van der Steege G, Schouten JP, Smit HA, et al. Level and course of FEV1 in relation to polymorphisms in NFE2L2 and KEAP1 in the general population. Respir Res. 2009;10:73.
27. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005;12:921-38. (Pubitemid 41823891)
28. Byrne S, Bede P, Elamin M, Kenna K, Lynch C, McLaughlin R, et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011;12:157-9.
29. von Otter M, Landgren S, Nilsson S, Celojevic D, Bergstrom P, Hakansson A, et al. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Medical Genetics. 2010;11:36.
30. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England). 2005; 21:263-5. (Pubitemid 40202029)
31. HapMap-Consortium. The international HapMap Project. Nature. 2003;426:789-96.
32. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science. 2002;296: 2225-9. (Pubitemid 34680308)
33. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Molecular Biology and Evolution. 1995;12:921-7.
34. Fukushima-Uesaka H, Saito Y, Maekawa K, Kamatani N, Kajio H, Kuzuya N, et al. Genetic variations and haplotype structures of transcriptional factor Nrf2 and its cytosolic reservoir protein Keap1 in Japanese. Drug Metab Pharmacokinet. 2007;22:212-9.
35. Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, Takahashi S, et al. Keap1-null mutation leads to post-natal lethality due to constitutive Nrf2 activation. Nature Genetics. 2003;35:238-45. (Pubitemid 37363177)
36. Taguchi K, Maher JM, Suzuki T, Kawatani Y, Motohashi H, Yamamoto M. Genetic analysis of cytoprotective functions supported by graded expression of Keap1. Molecular and Cellular Biology. 2010;30:3016-26.